Mark Leschly
CIK 1120545 · last filed 2026-07-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CARA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
152 W 57TH ST 23RD FL
NEW YORK, NY 10019
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CHPT | Director | 60,792 | $8.12 | $493.6K | $0 | 6 | 2026-07-22 |
| ChargePoint Holdings, Inc. (CHPT.WS) Delisted | Director | 439,446 | $20.53 | $9.02M | $0 | 4 | 2021-07-02 |
| NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Director | 3,766,667 | $1.54 | $5.80M | $0 | 4 | 2021-06-10 |
| Tvardi Therapeutics, Inc. (CARA) Delisted | 10%+ Owner | 99,113 | $15.96 | $1.58M | $81.17M | 3 | 2017-04-03 |
| Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Director | 2,787,674 | $10.19 | $28.41M | $11.71M | 8 | 2016-06-24 |
| IntraLinks Holdings, Inc. (IL) Delisted | 10%+ Owner | 3,858,495 | — | — | -$12.50M | 2 | 2015-09-16 |
| NephroGenex, Inc. (NRX) Delisted | 10%+ Owner | 1,073,907 | — | — | -$20.29M | 1 | 2015-01-06 |
| ReachLocal Inc (RLOC) Delisted | 10%+ Owner | 2,756,966 | — | — | -$18.42M | 1 | 2012-11-30 |
| VERENIUM CORP (VRNM) Delisted | Director | 216,264 | — | — | $0 | 3 | 2009-02-18 |
| TERCICA INC (TRCA) Delisted | Director | 885,304 | $7.87 | $6.97M | $0 | 2 | 2008-05-22 |
| NITROMED INC (NTMD) Delisted | Director | — | — | — | $0 | 2 | 2008-05-16 |
| SENOMYX INC (SNMX) Delisted | Director | — | — | — | $0 | 1 | 2007-06-04 |
Recent Filings · Page 2 of 4
39 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-03-02 | ChargePoint Holdings, Inc. (CHPT.WS) Delisted | Grant (A) | +382,996 | $0 | EDGAR |
| 2020-05-22 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-05-17 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-04-10 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Conv (C) | +3,766,667 | $0 | EDGAR |
| 2017-04-03 | Tvardi Therapeutics, Inc. (CARA) Delisted | Buy (P) | +3,000,000 | $54.57M | EDGAR |
| 2016-06-24 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Disp (D) | −794 | -$78.8K | EDGAR |
| 2016-03-18 | Tvardi Therapeutics, Inc. (CARA) Delisted | Buy (P) | +2,400,000 | $11.70M | EDGAR |
| 2015-09-16 | IntraLinks Holdings, Inc. (IL) Delisted | Sell (S) | −271,200 | -$2.56M | EDGAR |
| 2015-09-01 | IntraLinks Holdings, Inc. (IL) Delisted | Sell (S) | −970,136 | -$9.94M | EDGAR |
| 2015-06-11 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Grant (A) | +794 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.